Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial
Cobitolimod is a topically administered, DNA-based oligonucleotide that activates Toll-like receptor 9 (TLR9) It's a promising novel therapeutic target in ulcerative colitis and warrants further testing. The study was based on a computer-generated schedule and a centralized interactive voice and web response system.
